Cell, Gene And Specialty Drug Costs Intensify For Health Plans
A new Pharmaceutical Strategies Group survey of 228 benefits executives shows 43% of health plans rank controlling specialty drug costs as their top priority, ahead of total cost of care. Specialty medicines now consume more than half of prescription spending, with some employer plans reporting 60% or higher. The rise of high‑priced cell and gene therapies—such as a $475,000 leukemia treatment and a $3.5 million hemophilia B cure—has sparked major financial concerns for 85% of plans. Yet only 9% of respondents currently employ site‑of‑care strategies to curb oncology drug expenses, despite growing willingness to do so.
STAT+: Oruka’s Long-Acting Psoriasis Therapy Posts Strong Results in Mid-Stage Study
Oruka Therapeutics reported that its long‑acting injectable, ORKA‑001, achieved complete skin clearance in 63% of plaque‑psoriasis patients during a mid‑stage trial. The data suggest the drug can be administered just once per year, a stark contrast to current biologics that...
STAT+: Veradermics’ Hair Loss Drug Succeeds in Late-Stage Trial
Veradermics announced that its oral hair loss drug VDPHL01 met primary endpoints in a Phase III trial. Over six months, participants taking the pill grew 30‑33 hairs per square centimeter versus seven in the placebo group. Patient‑reported improvement reached 79‑86%, and...
Zepbound’s and Ozempic’s Greatest Benefit May Be Their Anti-Inflammatory Power
GLP‑1 drugs such as Ozempic and Zepbound are gaining recognition for anti‑inflammatory effects that go beyond weight loss and glucose control. Clinical data show semaglutide reduces C‑reactive protein by about 40% independent of weight loss and improves liver inflammation in...
AstraZeneca Reports FDA Approval of Saphnelo for Systemic Lupus Erythematosus (SLE)
The U.S. Food and Drug Administration has granted approval for AstraZeneca’s Saphnelo autoinjector (anifrolumab, 120 mg weekly) for adult patients with systemic lupus erythematosus (SLE) when used alongside standard of care. The decision follows the Phase III TULIP‑SC trial, which enrolled 367...
Novartis Secures Pair of Regulatory Wins for Skin Disease and Malaria Treatments
Novartis won two regulatory milestones: the European Commission approved its oral BTK inhibitor Rhapsido for adults with chronic spontaneous urticaria who have failed antihistamines, and the World Health Organization granted prequalification to Coartem Baby, an artemether‑lumefantrine formulation for infants weighing 2‑5 kg....
New NIHR-Funded TRC for Parkinson’s Disease
The National Institute for Health and Care Research (NIHR) has launched the Parkinson’s disease Translational Research Collaboration (PD‑TRC), the first of eight UK TRCs dedicated to Parkinson’s. Backed by NIHR and four major charities, the hub links 17 centres of...
Lilly Falls on Slower Start for Foundayo versus Wegovy
Eli Lilly’s oral GLP‑1 agonist Foundayo launched in early April with modest uptake, recording 1,390 prescriptions in week 1 and 3,707 in week 2, far below Novo Nordisk’s oral Wegovy, which logged over 3,000 fills in its first days and 18,410 in the second...
UK Biotech Could Be Bound for Recovery, BIA Report Reveals
UK biotech venture financing rebounded in Q1 2026, with total equity raised climbing 18% to £552 m ($746 m). Venture‑capital inflows also rose 17% to £516 m ($699 m), and 25 companies secured funding, up from 15 a year earlier. While public‑market activity stayed flat—no...
BrioHealth Secures FDA Approval to Launch BrioVAD System Trial
BrioHealth Solutions received conditional FDA approval to launch the Brio4Kids trial, testing its BrioVAD left ventricular assist device in children with advanced heart failure. Enrollment in the U.S. study is slated for mid‑2026, with initial data expected in the fourth...
Kyowa Kirin and Kura Initiate Phase II Trial of Ziftomenib for AML
Kyowa Kirin and Kura Oncology have opened a Japanese Phase II registrational study of the oral menin inhibitor ziftomenib in adults with relapsed or refractory NPM1‑mutated acute myeloid leukaemia. The single‑arm, open‑label trial will measure a composite complete remission rate (CR + CRh) as...
Review Questions Benefits of Anti-Amyloid Alzheimer’s Drugs
A Cochrane review of 17 clinical trials involving 20,342 patients with early Alzheimer’s disease found that anti‑amyloid drugs provide no clinically meaningful benefit on cognitive decline or dementia severity. The analysis also highlighted an increased risk of brain swelling and...
Sanofi Reports the CHMP Positive Opinion for Cenrifki (Tolebrutinib) to Treat Non-Relapsing SPMS
Sanofi’s oral BTK inhibitor Cenrifki (tolebrutinib) received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for treating secondary progressive multiple sclerosis (SPMS) without relapses in the past two years. The recommendation is...
AI in Single-Cell Analysis: Solving the Interpretation Gap
Single‑cell omics drives drug discovery but interpreting cell‑state annotations remains a bottleneck. Nygen Analytics introduced CyteType, an AI‑augmented platform that adds a traceable interpretation layer to existing pipelines, converting raw clusters into biologically meaningful labels. By combining marker‑gene analysis, literature...
Novartis’ Itvisma Receives the CHMP Positive Opinion for Spinal Muscular Atrophy
Novartis’ gene‑replacement therapy Itvisma (onasemnogene abeparvovec) received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for treating patients aged two years and older with 5q spinal muscular atrophy (SMA). The recommendation is...
Evonik: €80m for Biopharma CDMO Capacity in Slovakia
Evonik Industries is allocating roughly €80 million (about $87 million) to expand its fermentation plant in Slovenská Ľupča, Slovakia. The investment adds downstream capacity for pharmaceutical active ingredients and creates around 50 new jobs. The site, already a biotech hub producing spider‑silk protein...
In the Land of the Unblind: Are Psychedelics Really Better than Antidepressants?
Recent meta‑analysis comparing psychedelic‑assisted therapy (PAT) with open‑label antidepressant trials finds no clinically important difference in depression outcomes. While early PAT studies suggested larger effects, the analysis shows that functional unblinding limits any advantage, and open‑label antidepressants marginally outperform blinded...
Secretome-Mediated Antimicrobial and Immunomodulatory Activity of Lactobacillus Johnsonii Against Multidrug-Resistant Enteroaggregative Escherichia Coli
Researchers evaluated Lactobacillus johnsonii as a probiotic against a multidrug‑resistant enteroaggregative E. coli (EAEC) strain. The bacterium showed strong gastrointestinal tolerance, high auto‑aggregation (80 % at 4 h), and secretome‑driven inhibition of EAEC growth and biofilm formation, surpassing gentamicin. It also reduced...
Investment in UK Biotechs Shows Early Signs of Recovery, Report Says
Investment in UK biotechnology firms is rebounding after a mid‑2025 slowdown, according to the BioIndustry Association. In the first quarter of 2026, equity funding reached roughly $210 million, a 75% year‑over‑year rise. The number of deals climbed to 48, and the...
Eli Lilly and Company (LLY): Among the Best Stocks to Buy While the Market Is Down
Eli Lilly announced a strategic acquisition of Kelonia Therapeutics for up to $7 billion, with $3.25 billion paid upfront and up to $3.75 billion in milestones. Kelonia’s in‑body CAR‑T platform, led by Phase 1 candidate KLN‑1010, expands Lilly’s oncology pipeline beyond its dominant weight‑loss franchise....
StockWatch: Trump Order Lifts Psychedelic Drug Shares
President Donald Trump signed Executive Order 14401, directing the FDA to accelerate research and grant Commissioner’s National Priority Vouchers (CNPVs) to breakthrough psychedelic therapies. The order also mandates the HHS to allocate at least $50 million through ARPA‑H to partner with...
Novartis Antimalarial Clears Key WHO Review to Get the Combo Drug to Babies
Novartis’s Coartem Baby, the first antimalarial specifically designed for infants, has cleared the World Health Organization’s pre‑qualification review, allowing public‑sector and donor agencies to procure the drug in regions lacking robust regulatory systems. The formulation, a liquid‑dissolvable, cherry‑flavored version of artemether‑lumefantrine,...
Team Finds Surprising Food Source for Tumors
University of Rochester researchers discovered that cancer cells, particularly breast tumors, consume the antioxidant glutathione as a primary fuel source. Analysis of tumor fluid revealed abundant glutathione, and preclinical experiments showed that inhibiting its uptake slows tumor growth. The team...
Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 From the Ongoing EVERLAST-A Trial on April...
Oruka Therapeutics (Nasdaq: ORKA) announced it will present Week 16 data from its EVERLAST‑A Phase 2a trial of ORKA‑001, an investigational antibody for moderate‑to‑severe plaque psoriasis. The results will be released on Monday, April 27, 2026, during an 8:00 a.m. ET conference call and webcast. ORKA‑001...
Popular Weight-Loss Drug May Cut Heart Attack Risk by 54%, New Studies Find
Recent studies show tirzepatide, the GLP‑1/GIP agonist behind Zepbound and Mounjaro, slashes major cardiovascular events by 54% in patients after angioplasty and cuts complications by roughly 30% after aortic valve replacement. The benefits persisted for at least a year, translating...
Discovery of a Novel Vulnerability in Aggressive Lymphoma Could Change Future Therapy
Researchers at the University of Cologne’s Center for Molecular Medicine have identified the protein cFLIP as a critical driver of resistance in diffuse large B‑cell lymphoma (DLBCL), especially the ABC subtype. By overexpressing cFLIP, lymphoma cells block both intrinsic and...
‘Science Fiction’: How Life-Saving Organs Are Being Kept Alive Outside the Body
Organ shortages have driven a shift from static cold storage to active preservation methods. Normothermic machine perfusion (NMP) keeps kidneys and livers metabolically active in a nutrient‑rich, oxygenated circuit, extending viable time outside the body. An Australian first double transplant...
Letter to the Editor: Standard Chemoradiotherapy with Concurrent and Adjuvant Camrelizumab in Patients with High Risk Nasopharyngeal Carcinoma: Multicentre, Randomised,...
A phase‑3 BMJ trial showed that adding the PD‑1 inhibitor camrelizumab to concurrent chemoradiotherapy and 17 cycles of adjuvant maintenance extended progression‑free survival in high‑risk nasopharyngeal carcinoma, but overall survival did not improve significantly (HR 0.59, P = 0.19) after a median 39.9‑month...
Johnson & Johnson Joins TrumpRX
Johnson & Johnson has begun offering three branded diabetes drugs—Invokamet, Invokamet XR and Invokana—and the blood‑thinner Xarelto on the government‑run TrumpRX site and its own JNJ Direct platform. All three diabetes products are priced at $225, a 62% cut from...
Assessing the Roche Acquisition of SAGA Diagnostics and the Future of Molecular Residual Disease Monitoring
Roche has agreed to acquire Sweden‑based SAGA Diagnostics for up to $595 million, adding the ultra‑sensitive Pathlight™ MRD platform to its Foundation Medicine portfolio. Pathlight tracks tumor‑specific structural variants in circulating DNA, achieving sub‑one‑part‑per‑million detection limits and a 13.7‑month lead time...
New Cytometer Measures Cell Stiffness to Improve Disease Diagnosis
Researchers at Brown University and NIST introduced a mechanophenotyping cytometer that gauges cell stiffness via time‑of‑flight measurements in microfluidic channels. The device can analyze 60–100 cells per second, dramatically outpacing atomic force microscopy’s one‑cell‑per‑30‑seconds rate. By linking travel time to...
Natural Compound Obakulactone Shows Therapeutic Potential for Rheumatoid Arthritis
Researchers have identified obakulactone, a natural tetracyclic triterpenoid from Phellodendri cortex, as a promising therapeutic for rheumatoid arthritis (RA). In a CFA‑induced rat model, oral dosing (50‑200 mg·kg⁻¹·d⁻¹) over 21 days markedly reduced joint swelling, restored cartilage integrity, and modulated immune...
Deuruxolitinib Demonstrates Consistent Efficacy, Early Hair Regrowth in Severe Alopecia Areata
Deuruxolitinib (Leqselvi), an oral JAK1/JAK2 inhibitor from Sun Pharma, demonstrated robust efficacy in two pooled Phase 3 trials (THRIVE‑AA1 and THRIVE‑AA2) involving 867 adults with severe alopecia areata. At 24 weeks, 31% of treated patients achieved a SALT score of 20...
MASH Cirrhosis Trials Lack Consistent End Points
A new systematic review of phase 2 and 3 trials for metabolic dysfunction‑associated steatohepatitis (MASH) cirrhosis finds that endpoint selection is highly variable, with most studies relying on histologic improvement and few incorporating patient‑centered outcomes. The analysis identified only nine eligible...
CAR Therapies Could Offer New HBV, HIV Treatments
A new systematic review in Frontiers in Medicine evaluates 43 studies of virus‑directed CAR‑T and CAR‑NK therapies for chronic hepatitis B and HIV. Preclinical data show significant reductions in HIV p24 antigen, HBV surface antigen, and viral DNA, while early...
New Trial Prevents Cognitive Decline in Older Cancer Patients
A multicentric randomized controlled trial in India, called GOCog, tested a culturally tailored multidomain intervention to prevent chemotherapy‑induced cognitive decline in patients aged 60 and older. The program combined cognitive training, physical activity, nutrition guidance, and psycho‑educational support, and was...
KMT2C/D Loss Creates Targetable Cancer Weaknesses
Researchers have identified that loss of the histone‑modifying genes KMT2C or KMT2D creates exploitable weaknesses in cancer cells. Using a genome‑wide synthetic‑lethal screen, they uncovered a set of 12 drug candidates that selectively kill KMT2C/D‑deficient tumors. In mouse xenograft models,...
PE/PPE Proteins Drive Tuberculosis Drug Resistance
Researchers have identified the PE/PPE protein families as key drivers of drug resistance in Mycobacterium tuberculosis. Genetic analyses reveal that specific PE/PPE variants up‑regulate efflux pumps and alter cell‑wall permeability, reducing the efficacy of first‑line antibiotics such as isoniazid and...
Repeated Doses of Psilocybin Show Promise for Treating Obsessive-Compulsive Disorder
A randomized clinical trial found that weekly high‑dose psilocybin significantly reduced obsessive‑compulsive symptoms in treatment‑resistant patients. Fifteen adults received up to four doses over eight weeks, with 73 % achieving at least a 35 % drop in Yale‑Brown scores and 40 % attaining...
The Stanford Professor Behind an FDA-Cleared Cardiac AI Wants $1 Billion for His Next Company
Stanford associate professor James Zou is reportedly raising about $100 million at a $1 billion target valuation for his new startup Human Intelligence, which will apply AI across the entire biomedical discovery pipeline. Zou’s portfolio includes the FDA‑cleared cardiac‑AI EchoNet, a Nature‑published...
GLP-1 Drugs Linked to Cognitive Impairment, Though the Reason Why Probably Isn’t What You Expect
A retrospective analysis of nearly 65,000 type‑2 diabetes patients over ten years found that users of GLP‑1 agonists such as semaglutide experienced cognitive impairment at twice the rate of non‑users (2.6% vs 1.3%). Researchers attribute the higher incidence to a...
Oncolytics Could Re-Rate As Pelareorep Focuses On Registrational Paths
Oncolytics Biotech is refocusing its reovirus therapy Pelareorep on anal cancer and metastatic colorectal cancer, sharpening its commercial narrative. A colorectal cancer trial reported a striking 33% objective response rate, far exceeding the 6‑11% historical standard, prompting the FDA to...
Clinical Trial Finds No Difference in Fluid Treatment Options for Pediatric Sepsis
A NIH‑backed trial involving more than 9,000 children across five countries compared balanced crystalloid fluid with standard 0.9% saline for pediatric septic shock. The study found no significant differences in mortality, persistent kidney dysfunction, or need for renal‑replacement therapy between...
DEA Reschedules FDA-Approved Marijuana Products and State-Licensed Medical Marijuana to Schedule III
On April 22, 2026, Acting Attorney General Todd Blanche signed a final order moving FDA‑approved marijuana products and state‑licensed medical cannabis from Schedule I to Schedule III. The change eliminates the Section 280E tax disallowance for medical operators and creates an expedited DEA...
Inhaled Treprostinil Improves FVC in IPF Phase 3 Trial: Steven D. Nathan, MD
A phase 3 double‑blind trial (TETON‑2) evaluated inhaled treprostinil in 539 idiopathic pulmonary fibrosis patients and demonstrated a statistically significant preservation of forced vital capacity versus placebo. At 52 weeks, the treprostinil arm showed a median FVC decline of –49.9 mL compared with...
Efficacy of a Combination of Fipronil and Permethrin in Reducing the Risk of Dirofilaria Immitis Transmission to Dogs in Field...
A field trial in northern Greece evaluated Frontline Tri‑Act®, a topical fipronil‑permethrin blend, for heartworm prevention in dogs. Twenty‑four heartworm‑naïve Beagles were split 1:1 between monthly IVP treatment and an untreated control over seven months of peak mosquito activity. At study...
![[Comment] Antibody-Based Malaria Prevention in an Intense Perennial Transmission Setting](https://hixhlmpcokxhartfkpyi.supabase.co/storage/v1/object/public/images/thumbnails/a3263fcd8d733301ef10712d19f5c34a.webp)
[Comment] Antibody-Based Malaria Prevention in an Intense Perennial Transmission Setting
A recent phase‑2 trial of the monoclonal antibody L9LS in Kenyan children demonstrated high efficacy against Plasmodium falciparum in an intense, year‑round transmission setting. The study reported roughly 70% protection after a single dose, with a safety profile comparable to...
CMS Proposes Electronic Prior Authorization for Drugs
The Centers for Medicare & Medicaid Services (CMS) has issued a proposed rule to extend electronic prior authorization (e‑PA) to pharmaceuticals covered under both medical and pharmacy benefits. The rule mandates the use of Fast Healthcare Interoperability Resources (FHIR) APIs...
Patent Analysis Is Increasingly Shaping AI-Driven Target and Drug Candidate Selection
A new review in Nature Reviews Drug Discovery outlines how AI is expanding target identification by merging multi‑omics, knowledge graphs, and foundation models. The authors argue that patentability, commercial tractability, and competitor analysis should be evaluated alongside druggability and safety...
Bioprocessing Method Is a Critical Factor for IgM Oligomerization
Researchers compared fed‑batch and semi‑continuous perfusion bioprocesses for recombinant IgM production in CHO DG44 and CHO K1 cell lines, generating either pentameric (5IgM) or hexameric (6IgM) antibodies with or without a J‑chain. The perfusion approach, which continuously supplies fresh medium...